$ 75.00

ADD TO CART

ARA 290 - 10 mg

What is ARA-290?

ARA-290 (also known as Cibinetide) is an 11-amino-acid synthetic peptide derived from the structure of Erythropoietin (EPO). However, it is specifically engineered to be non-hematopoietic—meaning it provides the potent cell-protective and anti-inflammatory benefits of EPO without stimulating red blood cell production or thickening the blood.

It works by selectively binding to the Innate Repair Receptor (IRR), which activates the body's natural tissue-repair pathways and turns off chronic, destructive inflammation.

Primary Uses

ARA-290 is primarily researched and utilized for its neuroprotective and regenerative capabilities, particularly targeting the nervous and metabolic systems:

  • Neuropathic Pain Relief: Drastically reduces chronic neuropathic pain, specifically in conditions like Small Fiber Neuropathy (SFN).

  • Nerve Regeneration: Studies show it can actually stimulate the regrowth of damaged small nerve fibers.

  • Autoimmune & Inflammatory Conditions: Frequently studied for treating sarcoidosis-associated nerve damage and severe systemic inflammation.

  • Metabolic Support: Helps improve metabolic control and insulin sensitivity in type 2 diabetes models while protecting vulnerable tissues from diabetic complications.

How to Reconstitute ARA-290 (10mg)

Unlike Cerebrolysin or Lipo-B, ARA-290 almost always arrives as a freeze-dried (lyophilized) white powder in a 10mg glass vial. It must be reconstituted before use.

1. Choose Your Diluent

  • Use Bacteriostatic Water (0.9% benzyl alcohol) if you plan to use the vial over multiple days, as the preservative prevents bacterial growth.

2. Calculate Your Math

Because a 10mg vial holds a relatively large amount of peptide, adding 2 mL of bacteriostatic water is a standard, easy-to-calculate volume.

  • 10mg total peptide $\div$ 2 mL water = 5 mg of peptide per 1 mL of liquid.

  • If using a standard U-100 insulin syringe (where 100 units = 1 mL):

    • 20 units on the syringe = 1 mg of ARA-290

    • 40 units on the syringe = 2 mg of ARA-290

3. The Reconstitution Process

  1. Wipe the rubber stoppers of both the bacteriostatic water and the ARA-290 vial with an alcohol swab.

  2. Draw up exactly 2 mL of bacteriostatic water using a sterile syringe.

  3. Insert the needle into the ARA-290 vial at an angle, aiming the stream against the glass wall of the vial rather than shooting it directly into the powder.

  4. Let the vacuum pull the water in slowly. Do not rush it.

  5. Once inside, gently roll the vial between your palms until the powder dissolves completely into a clear, colorless liquid. Never shake the vial vigorously, as this can destroy the delicate peptide bonds.

Basic Safety & Storage Info

  • Route: Typically administered via Subcutaneous (SubQ) injection into fatty tissue (like the abdomen).

  • Storage: Before mixing, store the dry powder in the freezer or refrigerator. Once reconstituted, it must be stored in the refrigerator and used within 28 days. Do not freeze it after it has been mixed.

  • Side Effects: Generally well-tolerated in clinical trials, with a very low risk profile since it avoids the blood-clotting risks of standard EPO. Mild injection site irritation or transient headaches are occasionally reported.

Legal Disclaimer
These peptides and solutions are intended solely for laboratory and research purposes. They are not for human or animal use. Purchasers must comply with all applicable laws and regulations. By purchasing, you agree to indemnify and hold harmless our company from any claims arising from the handling or use of these products. Our liability is limited to the purchase price. Adopt all necessary safety precautions when handling the products. All product information and handling information is for informational/research purposes only. This is governed under Canadian law.

Shipping in Canada includes but is not limited to - British Columbia (Victoria, Vancouver, Surrey, Burnaby), Alberta (Edmonton, Calgary, Strathcona County), Saskatchewan (Regina, Saskatoon, Prince Albert), Manitoba (Winnipeg, Brandon), Ontario (Toronto, Ottawa, Mississauga, Hamilton), Quebec (Québec City, Montréal, Laval, Gatineau), New Brunswick (Fredericton, Saint John, Moncton), Nova Scotia (Halifax, Sydney), Prince Edward Island (Charlottetown, Summerside), Newfoundland and Labrador (St. John’s, Conception Bay South), Yukon (Whitehorse, Dawson City), Northwest Territories (Yellowknife, Hay River), Nunavut (Iqaluit, Arviat).